G1 Therapeutics Competitors and Similar CompaniesClear all

G1 Therapeutics's competitors and similar companies include Kadmon, Zyngenia, Bluebird Bio and Kite Pharma.

	G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.	Kadmon Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.	Zyngenia Zyngenia is a company developing biotherapeutics that simultaneously target multiple physiologic pathways.	Bluebird Bio Bluebird Bio is a developer of gene therapies for severe genetic diseases.	Kite Pharma Kite Pharma is a company developing cancer immunotherapy products based on cell therapy.
Founding Date	Founding Date 2008	Founding Date 2010	Founding Date 2009	Founding Date 1992	Founding Date 2009
Type	Type Public	Type Subsidiary	Type Private	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech drug development holding company pharma	Tags Healthcare biotech drug development genetics oncology pharma	Tags Healthcare biotech drug development genetics	Tags Healthcare biotech drug development oncology pharma therapy
Locations	Locations Durham, US HQ	Locations New York, US HQ Cambridge, US South Brunswick Township, US Warrendale, US	Locations Washington, US HQ	Locations Somerville, US HQ	Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more
Employees	Employees 17015% increase	Employees 44	Employees N/A	Employees 32338% decrease	Employees 3,9671% decrease
Valuation ($)	Valuation ($) 377.2 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 95.4 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $82.5m (FY, 2023)	Revenue (est.) $8.3m (FY, 2020)	Revenue (est.) N/A	Revenue (est.) $83.8m (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods $7.2m (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods $89.4m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit $75.3m (FY, 2023)	Gross profit N/A	Gross profit N/A	Gross profit ($5.6m) (FY, 2024)	Gross profit N/A
Net income	Net income ($48m) (FY, 2023)	Net income ($108.9m) (FY, 2020)	Net income N/A	Net income ($240.7m) (FY, 2024)	Net income N/A
Operating ⚠
Patents and Patent Applications	Patents and Patent Applications 350 (FY, 2020)	Patents and Patent Applications N/A	Patents and Patent Applications N/A	Patents and Patent Applications 1.2 k (FY, 2020)	Patents and Patent Applications N/A
Funding
Total funding raised	Total funding raised $ 289.6m	Total funding raised $ 21.3m	Total funding raised $ 25m	Total funding raised $ 409m	Total funding raised $ 85.3m